St. John's Wort
Identification
- Name
- St. John's Wort
- Accession Number
- DB01323
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Approved, Investigational, Nutraceutical
- Synonyms
- Common st johnswort flowering top
- Common st. john's wort flowering top
- Common st. john's wort herb
- Common st. johnswort flowering top
- Guanyejinsitao
- Hyperici herba
- Hypericum nachitschevanicum flowering top
- Hypericum perforatum flowering top
- Hypoxis hemerocallidea root extract
- Klamath weed flowering top
- Klamathweed flowering top
- Saint johns wort
- St john's wort
- St Johns Wort
- St. john’s wort
- St. johns wort
- St. johnswort flowering top
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbametapir The serum concentration of St. John's Wort can be increased when it is combined with Abametapir. Abatacept The metabolism of St. John's Wort can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be increased when combined with St. John's Wort. Abiraterone The metabolism of Abiraterone can be increased when combined with St. John's Wort. Acalabrutinib The metabolism of St. John's Wort can be increased when combined with Acalabrutinib. Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with St. John's Wort. Acebutolol The metabolism of Acebutolol can be decreased when combined with St. John's Wort. Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with St. John's Wort. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with St. John's Wort. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with St. John's Wort. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataEthical Herbals ST. John's Wort Tablet Oral Ashbury Research Corporation Not applicable Not applicable Canada 
Ethical Herbals ST. John's Wort Tablet Oral Ashbury Research Corporation Not applicable Not applicable Canada Felis Forte Capsules 425mg Capsule Oral Rhoxalpharma Inc Not applicable Not applicable Canada Felis Tablets 250mg Tablet Oral Rhoxalpharma Inc Not applicable Not applicable Canada ST. John's Wort Capsule Oral New Vision Nutritionals Company 1998-10-01 2002-11-20 Canada ST. John's Wort Capsule Oral Wn Pharmaceuticals Ltd. 1998-12-15 2006-08-08 Canada ST. John's Wort Capsule Oral Swiss Herbal Remedies Ltd. 1998-02-20 2008-08-15 Canada ST. John's Wort Capsule Oral Sisu Inc. 1998-02-11 2007-07-20 Canada ST. John's Wort Capsule Oral Wampole Brands 2003-02-01 2004-06-29 Canada ST. John's Wort Capsule Oral Pharmavite 1999-01-20 2004-07-20 Canada Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dynamiclear Rapid St. John's Wort (0.5 mg/1mL) + Calendula officinalis flower (0.5 mg/1mL) + Cupric sulfate pentahydrate (40 mg/1mL) Liquid Topical RX PHARMA-PACK, INC. 2019-02-06 2022-12-31 US 
Dynamiclear Rapid St. John's Wort (0.5 mg/1mL) + Calendula officinalis flower (0.5 mg/1mL) + Cupric sulfate pentahydrate (40 mg/1mL) Liquid Topical RX PHARMA-PACK, INC. 2019-02-06 2022-12-31 US Nite-caps St. John's Wort (20 mg) + Hops (40 mg) + Valerian (40 mg) Capsule Oral Flora Manufacturing And Distributing Ltd. 1991-12-31 2002-09-10 Canada S. R. Formula St. John's Wort (200 mg) + Valerian (133.2 mg) Liquid Oral Morinda Canada 2002-01-14 2006-07-12 Canada
Categories
- ATC Codes
- N06AX25 — Hyperici herba
- Drug Categories
- Antidepressive Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C19 Inducers (strength unknown)
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Inducers (strong)
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strong)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Herbs and Natural Products
- Hyperglycemia-Associated Agents
- Nervous System
- P-glycoprotein inducers
- Psychoanaleptics
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Classification
- Not classified
Chemical Identifiers
- UNII
- UFH8805FKA
- CAS number
- 84082-80-4
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- Synthesis Reference
Trevor Percival Castor, Theodore Abraham Tyler, Richard Joseph Student, "Methods for making Hypericum fractions and St. John's Wort products." U.S. Patent US6291241, issued December, 1998.
US6291241- General References
- Lecrubier Y, Clerc G, Didi R, Kieser M: Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6. [PubMed:12153829]
- Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K: The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine. 2006 Mar;13(4):215-21. Epub 2006 Jan 19. [PubMed:16423519]
- Authors unspecified: Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 Apr 10;287(14):1807-14. [PubMed:11939866]
- External Links
- PubChem Substance
- 46507869
- 1310069
- PharmGKB
- PA164924486
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Hypericum_perforatum
- AHFS Codes
- 92:01.00* — Herbs and Natural Products
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Diagnostic Pain 1 4 Completed Treatment Healthy Adults / Nootropic Potential of Hypericum and Alprazolam / Subclinical Anxious Adults 1 4 Completed Treatment Healthy Volunteers 1 3 Completed Treatment Atypical Depression 1 3 Completed Treatment Raynaud's Phenomenon 1 3 Terminated Treatment Pain 1 3 Unknown Status Diagnostic Peritoneal Carcinomatosis 1 3 Withdrawn Treatment Adult Solid Tumor / Breast Cancer / Head and Neck Carcinoma / Kidney and Urinary Cancer / Male Reproductive Cancer / Thorax and Respiratory Cancer 1 2 Completed Treatment Anxiety Disorders / Major Depressive Disorder (MDD) 1 2 Completed Treatment Attention Deficit Hyperactivity Disorder (ADHD) / Attention Deficit/Hyperactivity Disorder 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Guna Inc.
- Pekana Naturheilmittel GmbH
- Weleda Inc.
- Dosage Forms
Form Route Strength Liquid Topical Capsule Oral Tablet, coated 300 MG Liquid Oral Tablet Oral Liquid Oral Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Wenk M, Todesco L, Krahenbuhl S: Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol. 2004 Apr;57(4):495-9. [PubMed:15025748]
- Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]
- FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- SubstrateInducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [PubMed:21168483]
- Rahimi R, Abdollahi M: An update on the ability of St. John's wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):691-708. doi: 10.1517/17425255.2012.680886. [PubMed:22606944]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000 Dec;68(6):598-604. [PubMed:11180019]
Drug created on June 30, 2007 11:20 / Updated on January 26, 2021 22:46